Communiqué de presse : Dupixent, développé par Sanofi et Regeneron, a été approuvé au Japon comme premier médicament ciblé pour le traitement des adultes atteints de pemphigoïde bulleuse
View original at globenewswire.comCommuniqué de presse : Dupixent, développé par Sanofi et Regeneron, a été approuvé au Japon comme premier médicament ciblé pour le traitement des adultes atteints de pemphigoïde bulleuse Dupixent, développé par Sanofi et Regeneron, a été approuvé au Japon comme premier médicament ciblé pour le traitement des adultes at…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
Dupixent has been approved in Japan as the first targeted medication for treatment of adults with bullous pemphigoid
60% confidenceDupilumab has been studied in more than 60 clinical studies involving more than 12,000 patients with various chronic diseases partly due to type 2 inflammation
60% confidenceDupixent is a fully human monoclonal antibody that inhibits IL-4 and IL-13 pathway signaling and is not an immunosuppressant
60% confidenceMore than four times as many patients treated with Dupixent achieved sustained disease remission compared to placebo (18% vs. 4%; p=0.0250) at week 36
60% confidenceMore than 1.4 million patients are treated with Dupixent worldwide
60% confidenceDupixent has received regulatory authorizations in more than 60 countries for one or more indications
60% confidenceBullous pemphigoid is the seventh approved indication for Dupixent in Japan
60% confidenceTreatment-related adverse events occurred in 26% of patients treated with Dupixent and in 15% of patients on placebo, with conjunctivitis being the most frequently reported at 4%
60% confidenceDupixent's development program has shown significant clinical benefit and reduction in type 2 inflammation in phase 3 studies, establishing that IL-4 and IL-13 are two key and central factors of type 2 inflammation
60% confidence